Damien Conover is the Director of Healthcare Equity Research at Morningstar. With a focus on the healthcare industry, Damien provides analysis and insights on various companies and their performance in the market. His articles cover a range of topics including valuations, acquisitions, drug developments, and financial performance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
This information evolves through artificial intelligence and human feedback. Improve this profile .
Watching sales growth in Zepbound and Mounjaro, here's what we think of Eli Lilly stock.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/ECVXZPYGAJEWHOXQMUK6RKDJOM.jpg)
By: Damien Conover
We continue to believe AbbVie needs to expand its late-stage pipeline. Key Morningstar Metrics for AbbVie What We Thought of AbbVie's Earnings
Raising our fair value estimate of Eli Lilly stock. Key Morningstar Metrics for Eli Lilly What We Thought of Eli Lilly's Earnings
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/BSRZNDBL4JAMFPI4JSGK4QGDF4.jpg)
By: Damien Conover
We continue to view Pfizer stock as undervalued. Key Morningstar Metrics for Pfizer What We Thought of Pfizer's Earnings
With strong pricing power and sales growth of key drugs, here's what we think of Lilly's stock.
Our top healthcare sector picks are Moderna, Humana, and Baxter.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/Y5GCIVFOLREPXPM42MPMPEEMDI.jpg)
By: Damien Conover
Johnson & Johnson stock looks undervalued, with the market likely not fully appreciating the broad innovation across the firm's pipeline.
By: Damien Conover
Business Strategy and Outlook AbbVie holds a strong portfolio of marketed and pipeline drugs.
By: Damien Conover
We've increased our fair value estimate of AbbVie stock. Securities In This Article Key Morningstar Metrics for AbbVie
By: Damien Conover
What we Thought of AstraZeneca's Q2 Earnings We are holding steady to our £124/$78 fair value estimates (local/ADR) for AstraZeneca ( AZN ) following
(833) 317-6278 
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/T5MECJUE65CADONYJ7GARN2A3E.jpeg)
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/B26QQUGWL5BVLMVULGYK3QQASI.jpg)
